<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35466847</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-764X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Expert opinion on drug safety</Title>
          <ISOAbbreviation>Expert Opin Drug Saf</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>7</EndPage>
          <MedlinePgn>1-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14740338.2022.2069240</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Over half of Parkinson's disease (PD) patients develop psychotic symptoms, and PD psychosis (PDP) is associated with significant distress to patients, caregiver burden, and impairs quality of life. Pharmacological therapy is limited to atypical antipsychotics.</AbstractText>
          <AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">This review will summarize efficacy but will focus on the safety of antipsychotics for treating PDP, and in particular the off-target safety issues including cognitive impairment, sleep disturbance, cardiovascular effects, and motor function.</AbstractText>
          <AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">Pimavanserin is the only medication approved in the US for treating PDP, however clozapine is also considered efficacious. Despite lack of substantial evidence for efficacy, quetiapine is commonly used to treat PDP. Despite the effectiveness of pimavanserin and clozapine for treating PDP, a need exists for additional pharmacological agents that are effective for PDP while providing an acceptable safety and tolerability profile. Medications to treat PDP should avoid worsening motor function, and also minimize sleep disturbances, cognitive impairment, cardiovascular effects, and other non-motor safety concerns. A neutral effect or reduction in mortality risk associated with PD and PDP would be ideal, and low rate of discontinuation due to AEs is desirable. Lastly, medications that can be used safely in combination with other pharmacological agents is essential.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Isaacson</LastName>
            <ForeName>Stuart H</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Director, Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Citrome</LastName>
            <ForeName>Leslie</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Expert Opin Drug Saf</MedlineTA>
        <NlmUniqueID>101163027</NlmUniqueID>
        <ISSNLinking>1474-0338</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atypical antipsychotics</Keyword>
        <Keyword MajorTopicYN="N">Parkinsonâ€™s disease psychosis</Keyword>
        <Keyword MajorTopicYN="N">clozapine</Keyword>
        <Keyword MajorTopicYN="N">pimavanserin</Keyword>
        <Keyword MajorTopicYN="N">quetiapine</Keyword>
        <Keyword MajorTopicYN="N">safety</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>8</Hour>
          <Minute>56</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35466847</ArticleId>
        <ArticleId IdType="doi">10.1080/14740338.2022.2069240</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
